- Current report filing (8-K)
24 June 2010 - 7:17AM
Edgar (US Regulatory)
SECURITIES AND EXCHANGE
COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d)
of the Securities Exchange Act of 1934
Date of Report (Date of earliest event
reported):
June 18, 2010
MARTEK
BIOSCIENCES CORPORATION
(Exact
name of registrant as specified in its
charter)
Delaware
|
|
0-22354
|
|
52-1399362
|
(State
or other jurisdiction of
|
|
(Commission
File
|
|
(I.R.S.
Employer
|
incorporation
or organization)
|
|
Number)
|
|
Identification
No.)
|
6480 Dobbin Road, Columbia Maryland
|
|
21045
|
(Address
of principal executive offices)
|
|
(Zip
Code)
|
Registrants
telephone number, including area code:
(410) 740-0081
(Former
name or former address, if changed since last report)
Check the appropriate box below if the Form 8-K
filing is intended to simultaneously satisfy the filing obligation of the
registrant under any of the following provisions:
o
Written communications
pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
o
Soliciting material pursuant
to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
o
Pre-commencement
communications pursuant to Rule 14d-2(b) under the Exchange Act (17
CFR 240.14d-2(b))
o
Pre-commencement
communications pursuant to Rule 13e-4(c) under the Exchange Act (17
CFR 240.13e-4(c))
INFORMATION TO BE INCLUDED IN THE
REPORT
Section 1 Registrants
Business and Operations
Item 1.01 Entry into a Material Definitive Agreement.
On June 18, 2010, Martek Biosciences Corporation (Martek)
entered into an amendment (the Amendment) to its Supply Agreement, dated January 1,
2006, as amended on August 6, 2009 (the Supply Agreement), between
Martek and Mead Johnson & Company, LLC (Mead Johnson). The Amendment
is deemed effective as of June 1, 2010.
Prior to the Amendment, the Supply Agreement provided either
party with a right of early termination beginning after December 31,
2011. The Amendment eliminates such
early termination provision and, as a result,
the Supply Agreement will remain in effect through its full term, which
ends December 31, 2015. The
Amendment also amends the Supply Agreement to grant Mead Johnson an option for
a four year extension beyond December 31, 2015. Under the terms of the
Supply Agreement, as amended, Martek will continue as the global sole-source
supplier of DHA (docosahexaenoic acid) and ARA (arachidonic acid) for all Mead
Johnson infant formula products. Martek
will provide Mead Johnson with certain graduated price reductions over the
remaining term of the Supply Agreement.
2
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934,
the registrant has duly caused this report to be signed on its behalf by the
undersigned hereunto duly authorized.
|
Martek
Biosciences Corporation
|
|
|
|
Date:
June 23, 2010
|
By:
|
/s/
Peter L. Buzy
|
|
Peter L. Buzy
|
|
Chief
Financial
Officer
,
Treasurer
and
|
|
Executive
Vice
President for Finance
and
|
|
Administration
|
3
Martek (NASDAQ:MATK)
Historical Stock Chart
From Jun 2024 to Jul 2024
Martek (NASDAQ:MATK)
Historical Stock Chart
From Jul 2023 to Jul 2024